Features - VJNeurology

Subcutaneous efgartigimod PH20 granted approval by the FDA for the treatment of CIDP

On 21st June 2024, the U.S Food and Drug Administration approved subcutaneous efgartigimod alfa and hyaluronidase-qvfc combination injection (efgartigimod PH20;…

FDA grants approval of OTL-200 as the first gene therapy for children with metachromatic leukodystrophy

On March 18th 2024, the US Food and Drug Administration granted the approval of OTL-200 (atidarsagene autotemcel), an autologous hematopoietic…

FDA Issues Complete Response Letter for GA Depot in Relapsing Multiple Sclerosis

On 11th March 2024, Viatris Inc. announced that the U.S Food and Drug Administration (FDA) had issued a Complete Response…

ZODIAC trial demonstrates the impact of head-of-bed positioning in LVO stroke care

The ZODIAC study assessed whether maintaining a 0-degree head-of-bed (HOB) position, as opposed to an elevated 30-degree HOB position, enhances…

FDA grants approval to vamorolone for Duchenne muscular dystrophy: a breakthrough in efficacy and safety

On October 26, 2023, the US Food and Drug Administration (FDA) granted approval for Santhera Pharmaceuticals’ vamorolone oral suspension at…

Seed amplification assays: a novel development in synucleinopathy diagnosis

Synucleinopathies are a group of neurodegenerative disorders noted for the abnormal accumulation of misfolded α-synuclein (αSyn) which forms toxic inclusions…

FDA grants accelerated approval for SRP-9001 as the first ever gene therapy for Duchenne muscular dystrophy

On 22nd June, 2023, the U.S Food and Drug Administration (FDA) granted accelerated approval to Sarepta Therapeutics’ SRP-9001 (ELEVIDYS, delandistrogene…

What’s new in NMOSD? Updates on biomarkers and therapies

In recent years, significant advancements have been made in the management of neuromyelitis optica spectrum disorder (NMOSD). The introduction of…